iBio, Inc. Form 10-Q Summary
Reporting period: The provided filing is for the quarter and nine months ended March 31, 2020, iBio’s fiscal third quarter of 2020. The request metadata identifies “2019 Q3,” but the filing text clearly reports fiscal 2020 results. Financial statements are unaudited and presented under U.S. GAAP.
Business Context
iBio is a biologics contract development and manufacturing organization and biotechnology company using its plant-based FastPharming platform. Operations include CDMO services, proprietary product development, and facility design, technology transfer, and licensing. The company’s pipeline included IBIO-100 for fibrotic diseases, IBIO-200 for COVID-19, and IBIO-400 for classical swine fever.
iBio operates through iBio, Inc. and iBio CDMO. Its principal CDMO facility is located in Bryan, Texas and is subject to a 34-year finance lease with an affiliate of Eastern Capital Limited.
Key Financial Metrics
| Metric | Three months ended March 31, 2020 | Three months ended March 31, 2019 | Nine months ended March 31, 2020 | Nine months ended March 31, 2019 |
|---|---|---|---|---|
| Revenue | $96,000 | $527,000 | $518,000 | $1.223 million |
| Operating loss | $(4.064) million | $(3.770) million | $(11.074) million | $(11.735) million |
| Consolidated net loss | $(4.676) million | $(4.224) million | $(12.904) million | $(13.093) million |
| Net loss available to iBio stockholders | $(4.741) million | $(4.287) million | $(34.657) million | $(13.285) million |
| Basic and diluted loss per share | $(0.06) | $(0.22) | $(0.74) | $(0.71) |
Gross margins are not clearly disclosed in the filing. The company reported no separate cost-of-revenue line in the condensed statements of operations.
Balance Sheet and Liquidity
- Cash was $10.040 million at March 31, 2020, compared with $4.421 million at June 30, 2019.
- Total assets were $42.220 million, including $28.031 million of finance lease right-of-use assets.
- Total liabilities were $38.263 million and total equity was $3.957 million.
- Accumulated deficit was $146.882 million.
- Finance lease obligations totaled $32.379 million, including $295,000 current and $32.084 million non-current.
- Notes payable from the warrant exchange totaled $1.196 million at March 31, 2020. The balance was paid in full on May 1, 2020.
- Contract liabilities increased to $3.006 million from $1.279 million at June 30, 2019, primarily reflecting customer prepayments for services not yet performed.
Cash Flow
| Cash flow item | Nine months ended March 31, 2020 | Nine months ended March 31, 2019 |
|---|---|---|
| Cash used in operating activities | $(9.478) million | $(9.583) million |
| Cash used in investing activities | $(334,000) | $(817,000) |
| Cash provided by financing activities | $15.433 million | $3.503 million |
| Net change in cash | $5.619 million | $(6.897) million |
Material Changes Versus Prior Comparable Period
- Third-quarter revenue declined 82% to $96,000, primarily because CC-Pharming revenue declined to $75,000 from $467,000.
- Nine-month revenue declined 58% to $518,000. CC-Pharming revenue declined to $147,000 from $1.092 million, partly offset by $45,000 of revenue under the Lung Biotechnology agreement and higher revenue from other third-party customers.
- Third-quarter research and development expense declined 31% to $999,000; nine-month expense declined 26% to $2.864 million.
- Third-quarter general and administrative expense increased 11% to $3.161 million, principally because of a $450,000 sign-on bonus for CEO Thomas Isett and higher public-company costs.
- Nine-month general and administrative expense declined 4% to $8.728 million.
- Nine-month consolidated net loss improved modestly from $13.093 million to $12.904 million, but net loss available to iBio stockholders increased substantially because of a $21.560 million deemed dividend related to the down-round adjustment of Series A and Series B preferred stock.
- The company adopted ASC 842 effective July 1, 2019, reclassifying the facility and equipment lease as finance lease right-of-use assets and finance lease obligations. The adoption increased reported lease assets and liabilities and increased nine-month expense by approximately $788,000.
- Common shares outstanding increased from 20.152 million at June 30, 2019 to 107.360 million at March 31, 2020, primarily due to preferred-stock conversions, warrant exercises, and equity financing.
Guidance, Outlook, Risks, and Unusual Items
- Management expects significant expenses and operating losses to continue because no vaccine or therapeutic product candidate has been commercialized.
- Management stated that cash on hand at March 31, 2020, together with approximately $11 million of subsequent Lincoln Park equity purchases through the filing date, was expected to fund operations at least through June 1, 2021. This outlook depends on operating assumptions and continued access to financing.
- During fiscal 2020, the company received approximately $4.5 million from an October 2019 public offering, $5.8 million from Lincoln Park equity sales through March 31, 2020, and $6.4 million from warrant exercises. Through the filing date, Lincoln Park had purchased approximately $15.7 million of common stock under the 2020 purchase agreement.
- On April 16, 2020, iBio received a $600,000 Paycheck Protection Program loan. Forgiveness depends on compliance with applicable SBA requirements and approval; no assurance of forgiveness was provided.
- COVID-19 caused reduced manufacturing capacity because of social-distancing requirements and restrictions on laboratory access. Management could not estimate the full effect on operations or liquidity.
- iBio’s COVID-19 vaccine collaboration with CC-Pharming and its related patent efforts remained at an early stage, with no assurance of a successful product or proceeds.
- The company remained below certain NYSE American continued-listing standards. NYSE Regulation granted a plan period through December 9, 2020, subject to monitoring. Failure to regain compliance could lead to delisting proceedings.
- iBio is involved in ongoing litigation with Fraunhofer concerning intellectual property ownership, contractual obligations, technology transfer, and royalty provisions. The company stated that the outcome cannot currently be predicted.
- The company relies on additional equity or other financing and warned that financing may be unavailable or dilutive. Failure to obtain funding could require delaying or discontinuing programs, disposing of rights, or potentially ceasing operations.
Investor Verification Checklist
- Verify the reporting-period discrepancy: the filing is for fiscal third quarter 2020, not 2019 Q3.
- Reconcile cash runway assumptions with continuing operating cash use of approximately $9.5 million for nine months and the company’s dependence on equity financing.
- Review the terms, dilution implications, and remaining availability under the Lincoln Park 2020 purchase agreement.
- Assess the $32.4 million finance lease obligation, the $2.1 million annual base rent, and minimum future lease payments of approximately $82.5 million including interest.
- Monitor NYSE American compliance, the December 9, 2020 plan deadline, and any reverse-split or financing actions.
- Track COVID-19 operating effects, the status and potential forgiveness of the $600,000 PPP loan, and the company’s liquidity disclosures.
- Evaluate the commercial progress of CDMO contracts, including CC-Pharming and Lung Biotechnology, against the company’s very low reported revenue.
- Review the Fraunhofer litigation and any potential intellectual-property, royalty, or contractual consequences.
- Consider dilution from 28.925 million shares reserved for Series B preferred conversion, approximately 2.158 million outstanding stock options, and other equity awards.